Business
Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif., May 13, 2025--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported financial results for the first quarter ended March 31, 2025, and provided a business update.
About this update from Kezar Life Sciences, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1100,"height":360,"url":"https://media.zenfs.com/en/business-wire.com/f7ef5dae2c849a89404c8f8a37aaa0c9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wyir.ljJT_vnXKhctENqOg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMxNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/f7ef5dae2c849a89404c8f8a37aaa0c9","width":960,"height":314},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/4vfC2x9nQL0mfzIbPOVGSw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIyMDA7aD03MjA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/f7ef5dae2c849a89404c8f8a37aaa0c9","width":1100,"height":360}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Reported positive topline data from PORTOLA Phase 2a clinical trial evaluating zetomipzomib in patients with autoimmune hepatitis (AIH)","length":135,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Cash, cash equivalents and marketable securities totaled $114.4 million as of March 31, 2025","length":92,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":227,"olType":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 13, 2025--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported financial results for the first quarter ended March 31, 2025, and provided a business update.","length":343,"tagName":"p"},{"type":"text","content":""We shared exciting results this quarter from the PORTOLA trial, the first successful randomized study in treatment-refractory AIH," said Chris Kirk, CEO and co-founder of Kezar. "There has been almost no change over the last three decades in the treatment of this serious chronic disease, and patients and physicians are in need of new and effective therapies. We are encouraged by the promising safety and efficacy data in this difficult-to-treat patient population, in particular the durable and steroid-sparing remissions observed in patients treated with zetomipzomib. We continue to respond to the FDA Division of Hepatology and Nutrition on the partial clinical hold and are working toward achieving alignment on an appropriate tria...